HR + HER2- breast cancer typically requires endocrine therapy, often combined with chemotherapy and targeted therapy; HER2 + breast cancer primarily relies on targeted therapies such as trastuzumab; and TNBC is mainly treated with chemotherapy and immunotherapy [4, 238]. This evidence concerns the gene ERBB2 and breast cancer.